Doug Drysdale, CEO, Cybin

<p>In today’s episode of the Psychedelic Spotlight podcast, we sit down with Doug Drysdale, CEO of Cybin, a biotechnology company focused on creating new, effective, and accessible psychedelic-based therapies.</p><p>In our conversation, Doug talks about the company’s mission to revolutionize mental healthcare, how Cybin is delivering powerful and effective therapies, and why being the first psychedelic-based company to list on the New York Stock Exchange was a natural fit. Cybin can be found on the NYSE under the ticker symbol <strong>$CYBN</strong>.</p><p>*To learn more about Cybin and the work they’re doing, visit their website: <a href="https://www.cybin.com/">Cybin.com</a></p><p>*Subscribe to our newsletter to get the latest industry news: <a href="https://psychedelicspotlight.com/">PsychedelicSpotlight.com</a></p><p>Instagram: <a href="https://www.instagram.com/psycspotlight">@PsycSpotlight</a></p><p>Twitter: <a href="https://twitter.com/PsycSpotlight">@PsycSpotlight</a></p><p>Facebook: <a href="https://www.facebook.com/PsychedelicSpotlight">PsychedelicSpotlight</a></p><p>YouTube: <a href="https://bit.ly/3prTiCI">PsychedelicSpotlight</a></p><p>LinkedIn: <a href="https://www.linkedin.com/company/psychedelic-spotlight">Psychedelic-Spotlight</a></p><p>*This interview was recorded on September 2, 2021.</p>